Ginkgo Bioworks, a Boston-based biotech company that designs custom microbes for clients across multiple industries, has raised $275 million in a series D round of funding from Viking Global, Y Combinator’s Continuity Fund, Bill Gates’ Cascade Investment, and General Atlantic.
Founded in 2008, Ginkgo Bioworks specializes in synthetically creating cells for companies in the pharmaceutical, food, and fragrance industries, though it is also branching out into the agricultural realm. The startup recently announced a new joint venture with agricultural chemical giant Bayer to create crops that are capable of producing their own fertilizer.
An “organism company,” Ginkgo Bioworks effectively designs and makes its own DNA, and it represents a growing trend of companies recreating nature in the lab.
Ginkgo Bioworks had previously raised $154 million in outside funding, and with its latest gargantuan cash injection the company said that it will support its third foundry, Bioworks3, for prototyping and growing its engineered organism business across industries.
“We believe in the power of biology as a better way to make things, and we founded Ginkgo to make biology easier to engineer,” said Ginkgo Bioworks CEO Jason Kelly. “DNA is the code that will drive the next technological revolution, the way that digital code drove the revolution in information technology in the last half century. But unlike digital code, DNA code powers us — it is our food, our medicine, and increasingly, our technology. Our foundries are a platform that enable our partners to tap into the power of…